SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-18-119824
Filing Date
2018-04-17
Accepted
2018-04-17 16:21:03
Documents
2
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d572091dsc13da.htm SC 13D/A 84197
2 EX-99.1 d572091dex991.htm EX-99.1 5877
  Complete submission text file 0001193125-18-119824.txt   91770
Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Filed by) CIK: 0001297709 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
Novus Therapeutics, Inc. (Subject) CIK: 0001404281 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88334 | Film No.: 18759233
SIC: 2834 Pharmaceutical Preparations